Godavari Drugs Ltd
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
- Market Cap ₹ 91.8 Cr.
- Current Price ₹ 122
- High / Low ₹ 155 / 87.0
- Stock P/E 13.8
- Book Value ₹ 55.4
- Dividend Yield 0.00 %
- ROCE 14.4 %
- ROE 15.5 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -0.53%
- Working capital days have increased from 79.0 days to 113 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 140 | |
6 | 8 | 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 126 | |
Operating Profit | 2 | 2 | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 14 |
OPM % | 21% | 20% | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% |
0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
Interest | 0 | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
Profit before tax | 1 | 1 | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 8 |
Tax % | 33% | -121% | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | |
0 | 2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 7 | |
EPS in Rs | 0.64 | 2.06 | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 8.76 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 32% |
5 Years: | 13% |
3 Years: | 9% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 36% |
3 Years: | 11% |
TTM: | 92% |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 52% |
3 Years: | 28% |
1 Year: | 33% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 15% |
3 Years: | 15% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 0 | 2 | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 34 |
2 | 2 | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 59 | |
5 | 3 | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 27 | |
Total Liabilities | 15 | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 127 |
7 | 8 | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 34 | |
CWIP | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 18 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 7 | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 75 | |
Total Assets | 15 | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 127 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | |
-1 | -2 | -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | |
1 | 0 | 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | |
Net Cash Flow | 0 | -0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 20 | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 |
Inventory Days | 1,484 | 973 | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 |
Days Payable | 284 | 179 | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 |
Cash Conversion Cycle | 1,231 | 814 | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 |
Working Capital Days | 147 | 120 | 95 | 104 | 95 | 112 | 95 | 88 | 86 | 52 | 73 | 113 |
ROCE % | 9% | 8% | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
15 Nov - Publication of un-audited financial results for Q2 2024.
- Unaudited Financial Results For Quarter And Half-Year Ended September 30, 2024 14 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Of Godavari Drugs Limited (The Company) Held On Thursday 14Th November, 2024
14 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Intimation For Board Meeting
8 Nov - Board meeting on November 14 to approve financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Oct - Certificate under Regulation 74(5) for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company is in the business of Manufacturing APIs, drug intermediaries, and fine chemicals and caters to the global Life Science Industry. It has an active Loan License and Contract Manufacturing tie-ups with multinational companies for APIs and drug intermediates